These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 26606012)

  • 1. Coxib's Safety in Patients with Inflammatory Bowel Diseases: A Meta-analysis.
    Ribaldone DG; Fagoonee S; Astegiano M; De Angelis C; Smedile A; Caviglia GP; Petrini E; Greco A; Pellicano R
    Pain Physician; 2015 Nov; 18(6):599-607. PubMed ID: 26606012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
    Gunter BR; Butler KA; Wallace RL; Smith SM; Harirforoosh S
    J Clin Pharm Ther; 2017 Feb; 42(1):27-38. PubMed ID: 28019014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral cyclo-oxygenase 2 inhibitors versus other oral analgesics for acute soft tissue injury: systematic review and meta-analysis.
    Jones P; Lamdin R
    Clin Drug Investig; 2010; 30(7):419-37. PubMed ID: 20527999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of selective cyclooxygenase-2 inhibitors in exacerbation of inflammatory bowel disease: A systematic review and meta-analysis.
    Miao XP; Ouyang Q; Li HY; Wen ZH; Zhang DK; Cui XY
    Curr Ther Res Clin Exp; 2008 Jun; 69(3):181-91. PubMed ID: 24692797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
    Hur C; Chan AT; Tramontano AC; Gazelle GS
    Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COX-2 selective inhibitors in the treatment of osteoarthritis.
    Laine L; White WB; Rostom A; Hochberg M
    Semin Arthritis Rheum; 2008 Dec; 38(3):165-87. PubMed ID: 18177922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coxibs: a significant therapeutic opportunity.
    Gatti D; Adami S
    Acta Biomed; 2010 Dec; 81(3):217-24. PubMed ID: 22530460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis.
    Spiegel BM; Farid M; Dulai GS; Gralnek IM; Kanwal F
    Am J Med; 2006 May; 119(5):448.e27-36. PubMed ID: 16651060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature.
    Weberschock TB; Müller SM; Boehncke S; Boehncke WH
    Arch Dermatol Res; 2007 Jul; 299(4):169-75. PubMed ID: 17492455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?
    Kefalakes H; Stylianides TJ; Amanakis G; Kolios G
    Eur J Clin Pharmacol; 2009 Oct; 65(10):963-70. PubMed ID: 19711064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
    De Vecchis R; Baldi C; Di Biase G; Ariano C; Cioppa C; Giasi A; Valente L; Cantatrione S
    Minerva Cardioangiol; 2014 Dec; 62(6):437-48. PubMed ID: 25029569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
    Chen LC; Ashcroft DM
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):762-72. PubMed ID: 17457957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases.
    El Miedany Y; Youssef S; Ahmed I; El Gaafary M
    Am J Gastroenterol; 2006 Feb; 101(2):311-7. PubMed ID: 16454836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials.
    Chen LC; Ashcroft DM
    J Clin Pharm Ther; 2006 Dec; 31(6):565-76. PubMed ID: 17176361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.
    Hermann M; Ruschitzka F
    Ann Med; 2007; 39(1):18-27. PubMed ID: 17364448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review with meta-analysis: the gastrointestinal benefits of COX-2 selective inhibitors with concomitant use of low-dose aspirin.
    Yuan JQ; Yang M; Threapleton DE; Qi XS; Ye DQ; Mao C; Tang JL; Higgins JP
    Aliment Pharmacol Ther; 2016 Oct; 44(8):785-95. PubMed ID: 27534608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatotoxicity induced by coxibs: how concerned should we be?
    Bessone F; Hernandez N; Roma MG; Ridruejo E; Mendizabal M; Medina-Cáliz I; Robles-Díaz M; Lucena MI; Andrade RJ
    Expert Opin Drug Saf; 2016 Nov; 15(11):1463-1475. PubMed ID: 27537326
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.